Journal article
Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial
Abstract
BACKGROUND: The primary analysis of the INBUILD trial showed that in subjects with progressive fibrosing interstitial lung diseases (ILDs), nintedanib slowed the decline in forced vital capacity (FVC) over 52 weeks. We report the effects of nintedanib on ILD progression over the whole trial.
METHODS: Subjects with fibrosing ILDs other than idiopathic pulmonary fibrosis, who had ILD progression within the 24 months before screening despite …
Authors
Flaherty KR; Wells AU; Cottin V; Devaraj A; Inoue Y; Richeldi L; Walsh SLF; Kolb M; Koschel D; Moua T
Journal
European Respiratory Journal, Vol. 59, No. 3,
Publisher
European Respiratory Society (ERS)
Publication Date
March 2022
DOI
10.1183/13993003.04538-2020
ISSN
0903-1936